ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: FR-PO704

The Correlation Between Urinary microRNA-5195 and Renal Parameters in Patients with IgA Nephropathy

Session Information

Category: Glomerular Diseases

  • 1401 Glomerular Diseases: From Inflammation to Fibrosis

Authors

  • Kamei, Keita, Yamagata Daigaku, Yamagata, Yamagata, Japan
  • Suzuki, Natsuko, Yamagata Daigaku, Yamagata, Yamagata, Japan
  • Ichikawa, Kazunobu, Yamagata Daigaku, Yamagata, Yamagata, Japan
  • Watanabe, Masafumi, Yamagata Daigaku, Yamagata, Yamagata, Japan
  • Konta, Tsuneo, Yamagata Daigaku, Yamagata, Yamagata, Japan
Background

The microRNA-5195 (miR-5195) modulates cell proliferation by targeting the Cyclin L1 gene that regulates the cell cycle. In this study, we examined whether the urinary concentration of miR-5195 is related to clinicopathological parameters and short-term changes in renal function in patients with IgA nephropathy.

Methods

We extracted and quantified microRNAs in morning spot urine in 80 patients with IgA nephropathy at biopsy and four control subjects. Then we examined the relationship between clinical and histological parameters, one-year changes in eGFR, and urinary miR-5195. The concentrations of microRNAs and proteins were corrected to the concentration of urinary creatinine and were log-transformed for simple correlation analysis.

Results

The urinary excretion of miR-5195 was detected in all subjects, and the urinary concentration of miR-5195 in patients with IgA nephropathy was significantly higher than in controls. Among 80 patients with IgA nephropathy, urinary miR-5195 levels showed a significantly positive correlation with the urinary concentration of total microRNA (r=0.57), total protein (r=0.46), beta2-microglobulin (r=0.46), and N-acetyl-beta-D-glucosaminidase (NAG) (r=0.39), but not with baseline GFR, and urinary red blood cells. Concerning the histological parameters, the urinary miR-5195 levels showed a significant positive correlation with glomerular proliferation (r=0.24) but not with glomerular sclerosis and tubulointerstitial fibrosis. The one-year changes in eGFR after biopsy showed a significant inverse correlation with the urinary concentration of miR-5195 (r= -0.39) and total protein (r=-0.37) but not total microRNA, beta2-microglobulin, and NAG. The correlation between urinary miR-5195 and one-year eGFR change was stronger in the subjects without steroid treatment (r=0.47) than those with steroid treatment (r=0.38).

Conclusion

In this study, the urinary excretion of miR-5195 was correlated with clinical and histological parameters and one-year changes in renal function in patients with IgA nephropathy, suggesting that urinary miR-5195 might be a useful biomarker of IgA nephropathy.

Funding

  • Government Support – Non-U.S.